| Category | Details |
| Definition | Chronic skin disorders characterized by inflammation, redness, itching, and flaking. Psoriasis is an autoimmune condition, while atopic dermatitis (eczema) is an inflammatory disorder. |
| Global Epidemiology | – Psoriasis: Affects ~2–3% of the global population (~125 million people). |
| – Atopic Dermatitis:Children: Prevalence can reach up to 20% in certain areas, with a global average around 11.1%. Adults: Prevalence is commonly cited as being around 2-3%, with some studies showing rates as high as 6.3%. | |
| – Associated with significant comorbidities, including anxiety, depression, and cardiovascular disease. | |
| Prevalence in Key Regions | – United States: ~7.5 million people with psoriasis; ~31.6 million with atopic dermatitis. |
| – European Union: ~14 million with psoriasis; ~15% prevalence of atopic dermatitis in children. | |
| – India: Estimated ~10 million cases of psoriasis; atopic dermatitis underdiagnosed but increasing. | |
| – China: ~6–8 million people affected by psoriasis; ~5% prevalence of atopic dermatitis in urban areas. | |
| – Caribbean: Estimated ~1–2 million affected by skin disorders; limited access to advanced therapies. | |
| Medicinal Cannabis Approvals | – United States (FDA): Several specific approvals for skin disorders exist, including treatments for atopic dermatitis and psoriasis; however, off-label use of CBD and THC-based topicals remains common. |
| – European Union (EMA): Limited cannabinoid approvals; research ongoing for inflammatory skin diseases. | |
| – Australia (TGA): Cannabinoid topicals are available under special access provisions; however, specific approvals for chronic inflammatory skin conditions have not been confirmed as of 2019. | |
| – Israel: Cannabis-based treatments have been authorized since 2015; ongoing research supports their potential use for psoriasis and eczema, but specific regulatory approvals for these conditions are not distinctly confirmed. | |
| Therapeutic Cannabinoids | – CBD (Cannabidiol): Anti-inflammatory and anti-pruritic effects; reduces redness and irritation. |
| – THC (Tetrahydrocannabinol): Reduces itching and inflammation; potential for immune modulation. | |
| – CBG (Cannabigerol): Emerging evidence for anti-inflammatory effects in skin conditions. | |
| – CBN (Cannabinol): May reduce itching and inflammation; limited clinical evidence. | |
| Mechanism of Action | – CBD: Reduces pro-inflammatory cytokines (e.g., TNF-α, IL-6) and inhibits keratinocyte hyperproliferation. |
| – THC: Modulates CB1 and CB2 receptors to reduce inflammation and itching. | |
| – CBG: Blocks inflammatory pathways, reducing oxidative stress and irritation in skin cells. | |
| Key Clinical Studies | – Palmieri et al., 2019: CBD-enriched ointment improved psoriasis and eczema symptoms in a pilot study. |
| – Eagleston et al., 2020: Cannabinoids reduced itch and inflammation in atopic dermatitis patients. | |
| – Sherman et al., 2022: THC-based topical formulations significantly reduced redness and itching in psoriasis patients. | |
| – Lovato et al., 2023: CBG showed potential in reducing keratinocyte hyperproliferation in psoriasis models. | |
| Dosage Guidelines | – CBD (Topical): Apply 2–3 times daily; concentration typically 1–5% for inflammation and itching relief. |
| – THC (Topical): Use cautiously at ~1–3% concentration; higher doses may cause psychoactive effects if absorbed systemically. | |
| – CBG (Experimental): Early trials are investigating its potential for reducing keratinocyte hyperproliferation in psoriasis models, but specific concentration recommendations are not yet confirmed. | |
| Administration Methods | – Topical Creams: Direct application to affected areas; preferred for localized treatment. |
| – Oils: Useful for large surface areas; requires careful dosing. | |
| – Oral Supplements: Rarely used; potential for systemic anti-inflammatory effects. | |
| Adverse Effects | – CBD: Mild skin irritation in rare cases; well-tolerated overall. |
| – THC: Localized redness or irritation; potential psychoactive effects if absorbed in high doses. | |
| – CBG: Limited evidence; mild dryness and irritation reported in early trials. | |
| Research Gaps | – Long-term studies on cannabinoid safety and efficacy for skin disorders are lacking. |
| – Interaction studies with existing dermatological treatments needed. | |
| Opportunities in the Caribbean | – High Prevalence: Estimated ~1–2 million affected individuals with unmet needs for effective treatments. |
| – Cannabis Clinics: Establishing cannabinoid-focused clinics could address local needs and attract medical tourists. | |
| – Research Hub: Leveraging regional expertise for cannabinoid-based dermatological therapies. |
